Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma

Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma


Nov 16 A Japanese health ministry council has approved a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol Myers Squibb Co and marketed in the country by Ono Pharmaceutical Co Ltd. Opdivo, approved in Japan for treating advanced melanoma, non-small cell lung cancer and kidney cancer, has a current annual list price of 35 million yen . The 50 percent price cut will take effect in February, Ono Pharmaceutical said in an emailed statement on Wednesday.



from Biotech News